Bio Essence (BIOE) Total Non-Current Liabilities (2020 - 2026)
Bio Essence (BIOE) recorded quarterly Total Non-Current Liabilities of $55681.0 in Q1 2026, down 0.85% quarter-over-quarter from $56156.0 in Q4 2025, and down 98.28% on a YoY basis from $3.2 million in Q1 2025.
Bio Essence (BIOE) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Bio Essence's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $55681.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 98.28% year-over-year to $55681.0; the TTM figure through Mar 2026 stood at $55681.0 (down 98.28% YoY), while the FY2025 annual figure was $56156.0, down 87.45% from the prior year.
- Total Non-Current Liabilities was $55681.0 for Q1 2026 at Bio Essence, down from $56156.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.2 million in Q1 2025 to a low of $46219.0 in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $1.0 million across 5 years, with a median of $1.1 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities soared 1453.99% in 2025, then slumped 98.28% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.2 million in 2022, then sank by 96.24% to $46219.0 in 2023, then surged by 868.03% to $447414.0 in 2024, then plunged by 87.45% to $56156.0 in 2025, then decreased by 0.85% to $55681.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $55681.0 (Q1 2026), $56156.0 (Q4 2025), and $56493.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Bio Essence | - | - | 319,353.00 | 55,681.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55,681.00 |
| Dec 31, 2025 | 56,156.00 |
| Sep 30, 2025 | 56,493.00 |
| Jun 30, 2025 | 156,344.00 |
| Mar 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 447,414.00 |
| Sep 30, 2024 | 3.07 Mn |
| Mar 31, 2024 | 208,405.00 |
| Dec 31, 2023 | 46,219.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.41 Mn |
| Jun 30, 2021 | 1.42 Mn |
| Mar 31, 2021 | 1.59 Mn |